Cardiogenic shock continues to portend poor outcomes, conferring short-term mortality rates
of 30% to 50% despite recent scientific advances. Age is a nonmodifiable risk factor for …

Abstract Purpose of Review This paper reviews the latest literature on the growing field of
heart failure in the adult congenital heart disease population. Recent Findings After …

Aims Patients with heart failure (HF) with reduced ejection fraction (EF)(HFrEF), mildly
reduced EF (HFmrEF), and preserved EF (HFpEF) may all progress to advanced HF, but the …

One of the most challenging and prevalent side effects of LVAD implantation is that of right
heart failure (RHF) that may develop afterwards. The purpose of this study is to review and …

This comprehensive review highlights the significant advancements in Left Ventricular Assist
Device (LVAD) therapy, emphasizing its evolution from the early pulsatile flow systems to the …

Cardiac cachexia is characterized by unintentional catabolic weight loss, decreased
appetite, and inflammation and is common in patients with stage D (advanced) heart failure …

In recent years, a significant improvement in left ventricular assist device (LVAD) technology
has occurred, and the continuous-flow devices currently used can last more than 10 years in …

Heart Failure is a chronic and progressively deteriorating syndrome that has reached
epidemic proportions worldwide. Improved outcomes have been achieved with novel drugs …

Despite the withdrawal of the HeartWare Ventricular Assist Device (HVAD), hundreds of
patients are still supported with this continuous-flow pump, and the long-term management …

Right ventricular failure (RVF) is a significant cause of mortality in patients undergoing left
ventricular assist device (LVAD) implantation. Although right ventricular assist devices …